Today’s biopharmaceutical products often consist of complex
engineered synthetic protein sequences or fusions of sequences
that are not normally found together in nature.
MA:
The large companies with excess capacity are shedding that
capacity and looking for right-sized manufacturing. Drug
pipelines are inconsistent and it’s expensive to maintain idle capacity
for a pipeline that may or may not mature in the near ...